Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor

Seoul National University Hospital260 enrolled

Overview

Breast density change after short term use of aromatase inhibitor in postmenopausal ER positive breast cancer would predict endocrine responsiveness

Inclusion criteria ER positive breast cancer Postmenopause women Older than 60yr S/P bilateral salphingo-oophorectomy No menstruation history within 1yr and FSH\>30mIU/mL Ipsilateral invasive breast cancer Undergone curative resection No evidence of distant metastasis Capable of breast MRI

Study Type

OBSERVATIONAL

Enrollment

260

Conditions

Invasive Breast Cancer Estrogen Receptor Positive Breast Cancer

Eligibility

Sex: FEMALEMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ER positive invasive breast cancer Postmenopause women age 60yrs or older s/p bilateral salphingo-oophorectomy No history of menstruation and FSH\>30mIU Planned for aromatase inhibitor Unilateral breast cancer Curative resection No evidence of distant metastasis Exclusion Criteria: * Bilateral breast cancer Male breast cancer Acceptable for breast MRI Pregnancy or lactation

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

disease free survival

recurrence locoregional distant metastasis Confirmed by clinical imaging or pathology

Time frame: 5 year

Secondary Outcomes

breast density change

breast density change measured by cumulus(mammogram) and MRI(bilateral breast MRI) imagings taken after 6mos, 1yr, 2yr after endocrine therapy initiation

Time frame: 6mos, 1yr, 2yr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.